GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT02082665
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
Phase 3
Withdrawn
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: HavrixBiological: Cervarix™
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2015-07-20
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02082639
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
Phase 3
Completed
- Conditions
- Herpes ZosterHerpes Zoster Vaccine
- Interventions
- Biological: Herpes Zoster vaccine (GSK 1437173A)
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 651
- Registration Number
- NCT02075515
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Other: No Intervention
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT02076269
- Locations
- 🇧🇪
GSK Investigational Site, Edegem, Belgium
Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia
Phase 2
Terminated
- Conditions
- Anemia
- Interventions
- Drug: GSK1278863Drug: Placebo
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT02075463
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Amlodipine+RosuvastatinDrug: GSK3074477 FDC - 1Drug: GSK3074477 FDC - 2
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT02075619
- Locations
- 🇸🇬
GSK Investigational Site, Singapore, Singapore
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
Phase 2
Completed
- Conditions
- PsoriasisItchEczemaAllergy Symptoms
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 310
- Registration Number
- NCT02075632
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.
Phase 2
Completed
- Conditions
- Respiratory Disorders
- Interventions
- Drug: NaCl PlaceboBiological: NTHi-10-AS01E
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 145
- Registration Number
- NCT02075541
- Locations
- 🇬🇧
GSK Investigational Site, Wolverhampton, United Kingdom
A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays
Phase 4
Completed
- Conditions
- Meningococcal
- Interventions
- Biological: Menveo®Biological: Pneumovax 23®Biological: Prevnar 13®Biological: Boostrix®
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 359
- Registration Number
- NCT02072525
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Drug Use Investigation for Arepanrix® (H1N1)
Completed
- Conditions
- Influenza
- Interventions
- Biological: Arepanrix®
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3405
- Registration Number
- NCT02069496
© Copyright 2025. All Rights Reserved by MedPath